Vitrolife (VITR) Aperçu de l'action
Vitrolife AB (publ) fournit des produits de reproduction assistée en Europe, au Moyen-Orient, en Afrique, en Asie-Pacifique et dans les Amériques. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 2/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour VITR à partir de nos contrôles de risques.
VITR Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vitrolife AB (publ) Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | SEK 96.55 |
| Plus haut sur 52 semaines | SEK 153.50 |
| Plus bas sur 52 semaines | SEK 84.60 |
| Bêta | 1.72 |
| Variation sur 1 mois | 5.06% |
| Variation sur 3 mois | -10.68% |
| Variation sur 1 an | -32.01% |
| Variation sur 3 ans | -40.98% |
| Variation sur 5 ans | -78.85% |
| Évolution depuis l'introduction en bourse | 1,259.86% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.
Mise à jour du récit • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.Mise à jour du récit • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.Mise à jour du récit • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.Recent updates
Mise à jour du récit • Jul 14
VITR: Leadership Transition And Bearish Research Will Set Up Future Re-Rating Potential
Analysts have trimmed their fair value estimate for Vitrolife from SEK162.75 to SEK130.20, citing a slightly higher discount rate, modest adjustments to revenue growth and profit margin assumptions, and more conservative future P/E expectations following recent bearish research and a downgrade. What’s in the News for Vitrolife Vitrolife announced that CEO Bronwyn Brophy O'Connor has resigned to take a CEO role in another part of the medtech industry.Mise à jour du récit • Jun 30
VITR: Higher Discount Rate Reset Will Likely Unlock Future Upside
The Vitrolife analyst price target has been trimmed from SEK 230 to SEK 215, as analysts cite a higher required discount rate and a lower assumed future P/E multiple following more cautious research, including a downgrade from Pareto. What’s in the News for Vitrolife Vitrolife AB (publ) announced that CEO Bronwyn Brophy O'Connor has decided to leave the company to take a CEO role elsewhere in the medtech industry.Mise à jour du récit • Jun 16
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price expectations for Vitrolife, with the consensus target moving slightly lower to SEK 162.75 as some now see a more cautious outlook following recent downgrades. Key valuation inputs such as the discount rate and assumed future P/E have been adjusted only marginally.Mise à jour du récit • Jun 01
VITR: Governance Reforms And Softer Street Sentiment Will Support Future Upside Potential
Analysts have trimmed their price target on Vitrolife to SEK162.75 from SEK172.20, citing slightly higher discount rate assumptions, more cautious revenue growth expectations, softer profit margin estimates, and a modestly lower future P/E multiple following recent bearish Street research, including a downgrade from Pareto. What's in the News CEO Bronwyn Brophy O'Connor has resigned to take a CEO role elsewhere in the medtech industry, and the Board has started a recruitment process for a new CEO.Mise à jour du récit • May 12
VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential
Vitrolife's analyst price target has been adjusted from SEK 162.67 to SEK 172.20. Analysts point to modest tweaks in fair value assumptions, discount rate, revenue growth, profit margin and future P/E forecasts, even as some research houses, such as Pareto, have turned more cautious on the stock.Mise à jour du récit • Apr 27
VITR: Governance Reforms And Reset Expectations Will Support Future Upside Potential
Vitrolife’s analyst price target has been trimmed slightly from SEK 163.40 to about SEK 162.70, as analysts factor in updated assumptions on growth, margins and future P/E, and reflect the more cautious tone seen in recent research such as Pareto’s downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the revised target near SEK 162.70 as still implying upside relative to where caution has already been factored into growth, margin and P/E assumptions.Mise à jour du récit • Apr 12
VITR: Governance Amendments And Steady Assumptions Will Support Future Upside
Analysts have reduced their price target for Vitrolife to SEK 163.40 from SEK 176.75, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News Vitrolife AB (publ) has proposed amendments to its Articles of Association to be decided at the Annual General Meeting scheduled for May 5, 2026.Mise à jour du récit • Mar 29
VITR: Stable Fair Value And Tweaked Assumptions Will Support Future Upside
Analysts have kept Vitrolife's fair value estimate broadly unchanged at SEK 176.75, with only minor tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions, which has driven a very small adjustment to their price target framework. Valuation Changes Fair Value Estimate was kept stable at SEK 176.75, indicating no change in the central valuation outcome.Mise à jour du récit • Mar 13
VITR: Genetic Services Restructuring And Impairment Will Underpin Future Upside Potential
Analysts have kept their SEK 176.75 price target for Vitrolife broadly unchanged, making only very small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions to reflect fine tuning in their models rather than a shift in their overall view. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, tied to the Igenomix acquisition (company announcement).Mise à jour du récit • Feb 26
VITR: Genetic Services Restructuring And Impairment Will Support Future Upside Potential
Analysts have left their SEK 176.75 price target for Vitrolife unchanged, with only minimal tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (company announcement).Mise à jour du récit • Feb 11
VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife to €176.75 from €187, reflecting updated assumptions that include a higher discount rate, a higher future P/E multiple, and revised expectations for revenue growth and profit margins. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (Key Developments).Mise à jour du récit • Jan 27
VITR: Restructuring And Goodwill Impairment Will Drive Future Upside Potential
Analysts have trimmed their price target on Vitrolife from SEK188.75 to SEK187.00, reflecting adjustments to revenue growth and discount rate assumptions, along with updated views on profit margin and future P/E levels. What's in the News Vitrolife plans a restructuring program for its genetic services business, targeting annualised savings of SEK 65 million.Mise à jour du récit • Jan 10
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Vitrolife at SEK 188.75, with only minor technical adjustments to the discount rate and future P/E assumptions shaping the updated price target narrative. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, related to the Igenomix acquisition (company announcement).Mise à jour du récit • Dec 25
VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential
Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).Article d’analyse • Dec 18
There's No Escaping Vitrolife AB (publ)'s (STO:VITR) Muted Revenues
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a buy right now...Mise à jour du récit • Dec 11
VITR: Higher Long Term Revenue Outlook Will Support Further Upside
Analysts have nudged their price target on Vitrolife slightly higher to SEK 193.50 from SEK 193.00, citing marginally stronger long term revenue growth expectations that more than offset a modest uptick in the assumed discount rate and a slightly lower forecast profit margin. Valuation Changes Fair Value Estimate: unchanged at SEK 193.5 per share, indicating no revision to the intrinsic value despite minor model adjustments.Mise à jour du récit • Nov 27
VITR: Current Metrics And Stable Margins Will Support Further Upside
Analysts have maintained their fair value price target for Vitrolife at SEK 193.50, citing steady expectations for the company's growth, profitability, and valuation metrics. Valuation Changes Consensus Analyst Price Target: Unchanged at SEK 193.50.Article d’analyse • Nov 26
Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Mise à jour du récit • Nov 11
VITR: Stable Profitability And Marginal Rate Shift Will Drive Future Upside
Narrative Update on Vitrolife Analyst Price Target Vitrolife's analyst price target remains unchanged at SEK 193.50. Analysts cite only minor adjustments in growth and profitability forecasts, affirming their previous valuation stance.Mise à jour du récit • Oct 28
Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead
Narrative Update on Vitrolife Analyst Price Target Analysts have raised Vitrolife’s fair value estimate from SEK191.75 to SEK193.50. They highlight the company's improved profit margin outlook and stronger projected revenue growth as key drivers behind the revised target.Article d’analyse • Oct 28
Vitrolife AB (publ) (STO:VITR) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Vitrolife AB (publ) ( STO:VITR ) had a good week, as its shares rose 6.6% to close at kr151 following the...Mise à jour du récit • Oct 14
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Analysts have lowered their price target for Vitrolife from SEK 202.50 to SEK 191.75. This reflects updated expectations for slower revenue growth and profit margins, as well as a slightly higher discount rate.Article d’analyse • Aug 25
Vitrolife AB (publ)'s (STO:VITR) Shares Lagging The Industry But So Is The Business
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.3x might make it look like a strong buy right...Nouveau récit • Jul 28
US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery
Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize.Article d’analyse • Jul 08
Vitrolife AB (publ)'s (STO:VITR) Intrinsic Value Is Potentially 68% Above Its Share Price
Key Insights Vitrolife's estimated fair value is kr242 based on 2 Stage Free Cash Flow to Equity Current share price of...Article d’analyse • Jun 20
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Apr 25
Vitrolife AB (publ)'s (STO:VITR) Price Is Right But Growth Is Lacking
Vitrolife AB (publ)'s ( STO:VITR ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a buy right now...Article d’analyse • Mar 13
Here's Why Vitrolife (STO:VITR) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Feb 20
Estimating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr216 based on 2 Stage Free Cash Flow to Equity Vitrolife's kr213...Article d’analyse • Nov 27
Is Vitrolife (STO:VITR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Aug 21
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr204 Current share price of...Article d’analyse • Jul 20
Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Vitrolife AB (publ) ( STO:VITR ) just released its quarterly report and things are looking bullish. Vitrolife beat...Article d’analyse • Jul 18
Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
The Vitrolife AB (publ) ( STO:VITR ) share price has done very well over the last month, posting an excellent gain of...Article d’analyse • Apr 03
Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Mar 07
A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr215 With kr186 share price...Article d’analyse • Feb 05
Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
The yearly results for Vitrolife AB (publ) ( STO:VITR ) were released last week, making it a good time to revisit its...Article d’analyse • Jan 05
Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 62.5x Vitrolife AB (publ) ( STO:VITR ) may be sending very bearish signals...Article d’analyse • Dec 15
Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Key Insights Vitrolife's estimated fair value is kr193 based on 2 Stage Free Cash Flow to Equity With kr173 share...Article d’analyse • Nov 06
Is Vitrolife (STO:VITR) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendement pour les actionnaires
| VITR | SE Biotechs | SE Marché | |
|---|---|---|---|
| 7D | 11.7% | -3.3% | 1.3% |
| 1Y | -32.0% | 22.4% | 11.2% |
Rendement vs Industrie: VITR a sous-performé le secteur Swedish Biotechs qui a rapporté 22.4 % au cours de l'année écoulée.
Rendement vs marché: VITR a sous-performé le marché Swedish qui a rapporté 11.2 % au cours de l'année écoulée.
Volatilité des prix
| VITR volatility | |
|---|---|
| VITR Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.4% |
| 10% least volatile stocks in SE Market | 3.5% |
Cours de l'action stable: VITR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Swedish.
Volatilité au fil du temps: La volatilité hebdomadaire de VITR ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1989 | 1,126 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) fournit des produits de reproduction assistée en Europe, au Moyen-Orient, en Afrique, en Asie-Pacifique et dans les Amériques. Elle propose des aiguilles de traitement du sperme et de prélèvement d'ovocytes, des pipettes de micromanipulation, des systèmes time-lapse et des outils d'évaluation, des systèmes laser et d'imagerie, des milieux et de l'huile de FIV, des kits de transfert d'embryons, de cryoconservation et de génomique. La société fournit également des produits eWitness et Labware, tels que des plats, des pipettes, des tubes et VitroTemp.
Vitrolife AB (publ) Résumé des fondamentaux
| VITR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | SEK 11.82b |
| Bénéfices(TTM) | -SEK 5.01b |
| Recettes(TTM) | SEK 3.41b |
3.8x
Ratio P/S-2.6x
Ratio P/ELe site VITR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| VITR compte de résultat (TTM) | |
|---|---|
| Recettes | SEK 3.41b |
| Coût des recettes | SEK 1.41b |
| Marge brute | SEK 2.00b |
| Autres dépenses | SEK 7.01b |
| Les revenus | -SEK 5.01b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Oct 22, 2026
| Résultat par action (EPS) | -37.00 |
| Marge brute | 58.65% |
| Marge bénéficiaire nette | -147.17% |
| Ratio dettes/capitaux propres | 18.0% |
Quelles ont été les performances à long terme de VITR?
Voir les performances historiques et les comparaisonsDividendes
1.1%
Rendement actuel des dividendes-3%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/16 17:56 |
| Cours de l'action en fin de journée | 2026/07/16 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Vitrolife AB (publ) est couverte par 11 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kallum Titchmarsh | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |